Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsGlenmarkpharma

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to
    • Glenmark Pharma may touch Rs 1100: Vijay Chopra

      Glenmark Pharma may touch Rs 1100: Vijay Chopra

      Vijay Chopra of enochventures.com feels that Glenmark Pharma may touch Rs 1100.

    • Glenmark should start performing, target Rs 980: Amit Gupta

      Glenmark should start performing, target Rs 980: Amit Gupta

      Amit Gupta of ICICIdirect is of the view that Glenmark Pharma should start performing with a traget of Rs 980.

    • Buy Glenmark, Arvind, Alstom T&D; sell Andhra Bank: Thacker

      Buy Glenmark, Arvind, Alstom T&D; sell Andhra Bank: Thacker

      Mitesh Thacker of miteshthacker.com is of the view that one can buy Glenmark Pharma, Arvind and Alstom T&D and sell Andhra Bank.

    • Bull's Eye: Buy IOC, DLF, BEML, Glenmark, Ashok Leyland, MRPL

      Bull's Eye: Buy IOC, DLF, BEML, Glenmark, Ashok Leyland, MRPL

      Sameet Chavan of Angel Broking advises buying BEML with a target of Rs 972.

    • Sell Vedanta, Apollo Tyres; buy Glenmark Pharma: Ashwani Gujral

      Sell Vedanta, Apollo Tyres; buy Glenmark Pharma: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com recommends selling Vedanta and Apollo Tyres and buy Glenmark Pharma.

    • Stock calls from Citi, Credit Suisse, Morgan Stanley......

      Stock calls from Citi, Credit Suisse, Morgan Stanley......

      Citi has a buy call on the stock with a target of Rs 790 per share, saying it remains top pick amongst small caps after quarterly earnings.

    • Buy Glenmark Pharma, ICICI Bank: Mitesh Thacker

      Buy Glenmark Pharma, ICICI Bank: Mitesh Thacker

      Mitesh Thacker of miteshthacker.com is of the view that one can buy Glenmark Pharma and ICICI Bank.

    • Buy Glenmark Pharma, JSW Energy: Mitesh Thacker

      Buy Glenmark Pharma, JSW Energy: Mitesh Thacker

      Mitesh Thacker of miteshthacker.com is of the view that one can buy Glenmark Pharma and JSW Energy.

    • Buy Yes Bank, Apollo Tyres, PNB; sell HDFC, ITC: Ashwani Gujral

      Buy Yes Bank, Apollo Tyres, PNB; sell HDFC, ITC: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com is of the view that one can buy Yes Bank, Apollo Tyres, PNB and pharma stocks and advises selling HDFC and ITC.

    • Buy Glenmark Pharma, IRB Infra, Tata Steel: Sandeep Wagle

      Buy Glenmark Pharma, IRB Infra, Tata Steel: Sandeep Wagle

      Sandeep Wagle of powermywealth.com is of the view that one can buy Glenmark Pharma, IRB Infra and Tata Steel.

    • Buy Glenmark Pharma; sell Cairn India: Mitesh Thacker

      Buy Glenmark Pharma; sell Cairn India: Mitesh Thacker

      Mitesh Thacker of miteshthacker.com recommends buying Glenmark Pharma and sell Cairn India.

    • Buy ICICI Bank, Glenmark Pharma, PNB: Ashwani Gujral

      Buy ICICI Bank, Glenmark Pharma, PNB: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com recommends buying ICICI Bank, Glenmark Pharma and PNB.

    • Sell Ceat, Ambuja Cements, Glenmark; buy Taj GVK: Mitesh Thacker

      Sell Ceat, Ambuja Cements, Glenmark; buy Taj GVK: Mitesh Thacker

      Mitesh Thacker of miteshthacker.com recommends selling Ceat, Ambuja Cements, Glenmark Pharmaceuticals and Shriram Transport Finance and buy Taj GVK Hotels & Resorts.

    • Here are Ajay Bodke's top trading ideas

      Here are Ajay Bodke's top trading ideas

      Watch the interview of Ajay Bodke of Prabhudas Lilladher with Latha Venkatesh, Anuj Singhal & Sonia Shenoy on CNBC-TV18, in which he shared his readings and outlook on market and specific stocks.

    • Investment strategies: Top 5 stocks that you can focus today

      Investment strategies: Top 5 stocks that you can focus today

      CLSA says large deal loss puts FY17 guidance of Infosys at risk after weak Q1. It may impact FY17 revenue by USD 50-100 million and FY18 revenue by USD 100-200 million. Its sya RBS deal cancellation puts FY17 revenue guidance at risk by 0.5-1 percent.

    • Go long in private banks; short PSU banks, short IFCI: Thacker

      Go long in private banks; short PSU banks, short IFCI: Thacker

      Mitesh Thacker of miteshthacker.com is of the view that one can go long in private banks and short PSU banks and advises shorting IFCI.

    • Bull's Eye: Sell Apollo Tyres, Glenmark Pharma, M&M Fin; buy MRF

      Bull's Eye: Sell Apollo Tyres, Glenmark Pharma, M&M Fin; buy MRF

      Rakesh Bansal of RK Global advises buying Dhampur Sugar with a target of Rs 142.

    • Sell Glenmark, Bharat Financial may test Rs 780-810: Rajat Bose

      Sell Glenmark, Bharat Financial may test Rs 780-810: Rajat Bose

      Rajat Bose of rajatkbose.com recommends selling Glenmark Pharma and feels that Bharat Financial Inclusion may test Rs 780-810.

    • See break out in BPCL, pick Glenmark Pharma: Sudarshan Sukhani

      See break out in BPCL, pick Glenmark Pharma: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may see imminent break out in BPCL and has Glenmark Pharma as the choice for the day.

    • Here are a few stock ideas from Ajay Bodke

      Here are a few stock ideas from Ajay Bodke

      In an interview to CNBC-TV18, Ajay Bodke, CEO & Chief Portfolio Manager (PMS) at Prabhudas Lilladher Pvt. Ltd shared his readings and outlook on market, specific stocks and sectors.

    • Buy Power Grid, BHEL; sell Glenmark Pharma: Sandeep Wagle

      Buy Power Grid, BHEL; sell Glenmark Pharma: Sandeep Wagle

      Sandeep Wagle of powermywealth.com recommends buying Power Grid and BHEL and advises selling Glenmark Pharma while Maruti Suzuki may test Rs 4800.

    • Glenmark may test Rs 900 in 5-6 months, says Neeraj Deewan

      Glenmark may test Rs 900 in 5-6 months, says Neeraj Deewan

      Neeraj Deewan of Quantum Securities is of the view that Glenmark Pharma may test Rs 900 in next 5-6 months.

    • Prefer Glenmark, Alembic Pharma, Alkem Labs: Mehraboon Irani

      Prefer Glenmark, Alembic Pharma, Alkem Labs: Mehraboon Irani

      Mehraboon Irani of Nirmal Bang Securities is of the view that one may prefer Glenmark Pharma, Alembic Pharma and Alkem Laboratories.

    • Tulsian on Ricoh India: Rush for exit, there is no hope

      Tulsian on Ricoh India: Rush for exit, there is no hope

      In an interview to CNBC-TV18, SP Tulsian of sptulsian.com shared his reading and outlook on the fundamental side of the market as well as on specific stocks and sectors.

    • Bull's Eye: Buy Marico, Balrampur Chini, Idea; sell Sintex

      Bull's Eye: Buy Marico, Balrampur Chini, Idea; sell Sintex

      According to Krish Subramanyam of Altamount Capital, one may buy Idea Cellular with a target of Rs 111.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347